NCT05523440View on ClinicalTrials.gov

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

January 8, 2025

Study Completion Date

January 8, 2025

Conditions
Recurrent Endometrial CarcinomaRecurrent Ovarian CarcinomaARID1A Gene Mutation
Interventions
DRUG

Bevacizumab

Bevacizumab infusion.

DRUG

Niraparib

Niraparib oral capsule.

Trial Locations (2)

22903

University of Virginia Comprehensive Cancer Center, Charlottesville

73104

University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

University of Virginia

OTHER

lead

University of Oklahoma

OTHER